chartexchange

SABS
SAB Biotherapeutics, Inc. Common Stock
stockNASDAQ

Market OpenNov 19, 2026 3:33:46 PM EST
2.91USD-8.906%(-0.29)1,232,440
2.9000Bid2.9400Ask0.0400Spread
Loading…
Loading…
259.01M
Healthcare
Biotechnology
HQ
Sioux Falls, SD, USA
Previous Close
$3.20
Beta
1.07
52-Week High
$5.15 2026-03-12
52-Week Low
$2.44 2026-10-19
SMA 50
$3.09
SMA 200
$3.61
Avg. Vol 10D
729,792
Avg. Vol 30D
689,332
Avg. Vol 90D
561,740
Relative Vol
1.92
80.72M
4.9000%
3,600,000
115
Jan 5, 2024 · 1-for-10 (reverse)
SABS Profile

sab biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.

SABS Performance
PeriodPriceDateChangeBeta
1W3.082026-11-12-6.66%1.051
1M2.602026-10-19+10.58%1.062
3M3.782026-08-19-23.94%1.115
6M3.552026-05-19-19.01%1.410
1Y3.832025-11-19-24.93%1.068
2Y3.242024-11-19-11.27%—
5Y110.302021-11-19-97.39%0.785
SABS Stock Summary

SAB Biotherapeutics, Inc. Common Stock (NASDAQ:SABS) stock price today is $2.88, and today's volume is 1,320,109. SABS is down 10.156% today. The 30 day average volume is 689,332. SABS market cap is $259.01M with 90.09M shares outstanding.